CUHK PhD Candidates / Research Assistants: Neuroscience and Neurodegenerative Disease Recruitment

CUHK PhD Candidates / Research Assistants: Neuroscience and Neurodegenerative Disease Recruitment

Executive Verdict

Strong thematic fit; verify the PhD route, funding and current availability before applying.

This EURAXESS advert recruits PhD candidates/Research Assistants for Prof. Yingjun Liu's team at the Gerald Choa Neuroscience Institute and School of Biomedical Sciences. It names three broad themes: mechanisms of brain aging and neurodegenerative disease, anti-brain-aging and neuroprotective interventions, and brain-research technologies based on CRISPR and organotypic slice culture. It does not assign a specific disease model, thesis topic or first-year experiment. The themes align with the supervisor's stated interests (EURAXESS vacancy, GCNI profile); CUHK's research portal confirms his appointments in both named units (CUHK research profile).

The saved listing gives a deadline of 30 November 2026, 23:59 Hong Kong time, and also displays “STATUS: EXPIRED”; current acceptance has not been verified. Its metadata labels the work “PhD Positions,” full-time and temporary, and says it is not funded through the EU Research Framework Programme; the offer description seeks PhD candidates/Research Assistants and lists two offers. CUHK's separate MPhil-PhD in Biomedical Sciences page gives a 2026/27 programme deadline that has already passed; that admissions deadline is distinct from the vacancy deadline (programme page). The advert does not specify stipend or salary, tuition, start date, contract term, or whether both offers lead to PhD enrolment. Confirm these in writing before treating it as a funded doctoral place.

School, Programme, and Location Signal

CUHK has a high institutional signal. Its own ranking summary lists the university at #18 worldwide in QS World University Rankings 2027, #28 worldwide in U.S. News Best Global Universities 2026-2027, and #41 worldwide in Times Higher Education Rankings 2026 (CUHK rankings). The Graduate School also describes a large postgraduate environment, with more than 17,900 postgraduate students and 240+ postgraduate programmes across 62 graduate divisions in 2026-27 (Graduate School overview). External ranking sources broadly support that signal: THE lists CUHK as #41 in World University Rankings 2026 and #26 in Medical and Health (THE profile), while ShanghaiRanking identifies Clinical Medicine as one of CUHK's strongest ranked subjects in 2025 (ShanghaiRanking profile).

The most relevant formal degree context is the MPhil-PhD in Biomedical Sciences in CUHK's Faculty of Medicine. The programme's fields include Neural, Vascular, and Metabolic Biology, which is the closest stated fit to this project. The PhD stream includes compulsory and elective coursework, annual seminars, thesis research registration, candidacy examination, thesis proposal, and final thesis defence (programme page). CU Medicine describes Biomedical Sciences as an interdisciplinary and translational environment with core laboratories in microscopy/imaging, histology, flow cytometry, proteomics, macromolecular and microarray work, bio-fabrication, transgenic work, and animal holding (CU Medicine programme page). That infrastructure is relevant because the project asks for CRISPR, AAV, animal models, tissue culture, high-throughput screening, sequencing, and computational biology.

The location signal is mixed in the usual Hong Kong way: strong international research connectivity and biomedical ecosystem, but high cost pressure if housing is not subsidized or on-campus.

Supervisor and Lab Assessment

Supervisor Research Directions

Prof. Yingjun Liu's profile is unusually well matched to the project description. GCNI states that he trained in glial cells and neuroinflammation in Parkinson's disease, then prion-related brain disorders in Adriano Aguzzi's lab at the University of Zurich, and later in vivo whole-genome CRISPR screening at ETH Zurich. The same page lists research interests in brain aging, neurodegenerative diseases, therapeutic interventions, CRISPR, and organotypic slice culture technologies (GCNI profile). An ETH Zurich profile from his postdoctoral period similarly frames his work around new technologies for neurodegenerative disease research and whole-genome CRISPR-Cas9 screening (ETH profile).

This means the project is not a generic neuroscience opening. It appears to be built around the supervisor's established technical and biological agenda: use perturbational tools and brain model systems to discover mechanisms and intervention points in brain aging and neurodegeneration.

Recent Important Publications

1. NG2 glia protect against prion neurotoxicity by inhibiting microglia-to-neuron prostaglandin E2 signaling (Nature Neuroscience, 2024). This paper, led by Liu and Aguzzi, identifies a protective role for NG2 glia and implicates microglial PGE2 signaling as a modifiable neurotoxicity pathway (Nature Neuroscience). It is directly relevant to a student interested in glia-neuron interaction, neuroinflammation, and disease mechanisms.

2. Brain aging is faithfully modelled in organotypic brain slices and accelerated by prions (Communications Biology, 2022). This paper establishes cultured mouse brain slices as a tractable mammalian brain-aging model and reports that prions accelerate aging-related signatures (DOI). This is the most direct evidence for the advertised organotypic slice culture and brain-aging technology line.

3. An arrayed genome-wide perturbation screen identifies the ribonucleoprotein Hnrnpk as rate-limiting for prion propagation (The EMBO Journal, 2022). This paper includes Liu and uses a high-throughput assay plus genome-wide perturbation to identify host factors influencing prion propagation (EMBO Journal). It supports the project's high-throughput genetic/pharmacological screening direction.

4. EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation (Cell, 2026). Liu appears among the co-authors in a mechanistic neuroimmunology study linking EBV infection, HLA-DR15 and myelin peptide presentation in multiple sclerosis (Cell). This is less central than the prion/aging papers but shows connection to broader neurological disease mechanisms.

Lab, Resources, and Collaboration Environment

The lab's scientific platform looks promising, but some operational details are not yet visible. The supervisor has a strong publication and training trajectory, and CUHK Medicine describes communal biomedical infrastructure that is relevant to this project (CU Medicine programme page). However, the CUHK group appears relatively new. Applicants should therefore verify current lab size, active grants, AAV access, animal ethics approvals, slice-culture setup, sequencing support, computational mentorship, and whether the first projects are already funded.

Research Direction and Field Outlook

Field Momentum

The field has strong long-term momentum. WHO reports that 57 million people had dementia in 2021, with nearly 10 million new cases each year, and Alzheimer's disease accounts for 60-70% of dementia cases (WHO dementia fact sheet). That burden keeps mechanistic and therapeutic neurodegeneration research strategically important.

Scientifically, this project sits in a current frontier area. A 2024 Nature Reviews Neuroscience review highlights selective vulnerability, non-cell-autonomous mechanisms, single-cell transcriptomics, CRISPR-based screens, and human cell-based disease models as key approaches in modern neurodegeneration research (Nature Reviews Neuroscience). A separate 2024 Nature paper using CRISPR-Cas9 screens to identify regulators of neural stem-cell aging reinforces that perturbational screening is now a live aging/neuroscience method, not only a cancer-genomics tool (Nature).

Potential Research Angles

The advert gives broad themes but no assigned model or complete student workflow. The following are possible directions inferred from the advert and the supervisor's published work, not promised doctoral tasks:

• CRISPR or genetic screens to identify regulators of brain aging and neurodegeneration.
• Organotypic slice culture as an intermediate model between cell culture and whole-animal disease models.
• Glia-microglia-neuron signaling mechanisms in toxic or protective neurodegenerative states.
• AAV-enabled perturbation or delivery strategies in brain models.
• Single-cell or bulk sequencing to map molecular signatures of aging, prion-like toxicity, neuroinflammation, or intervention response.
• Pharmacological screening for anti-brain-aging or neuroprotective interventions.

The strongest thesis direction would combine a mechanistic hypothesis with a platform output. For example: identify a pathway by screen, validate it in slice culture or animal models, then connect it to transcriptomic or cell-cell signaling changes.

Career and Market Outlook

Career optionality is strongest for candidates who leave with both wet-lab and computational literacy. Hong Kong's official talent information highlights demand in deep tech, biopharma, bioinformatics and related innovation roles, and notes rising R&D expenditure (Hong Kong Talent Engage). The Innovation, Technology and Industry Bureau identifies life and health technologies among Hong Kong's strategic technology industries and describes an ecosystem anchored in universities, I&T parks, R&D institutions and InnoHK (ITIB press release).

The realistic interpretation is positive but not guaranteed: this PhD direction could support later roles in academic neuroscience, translational neurobiology, gene therapy, target discovery, preclinical disease modeling, sequencing/bioinformatics, platform science or biotech R&D. Academic tenure-track paths remain competitive, and project success will depend heavily on publications, technical depth and collaboration network.

Funding, Application, and Living Cost

Funding is the biggest verification item. CUHK Graduate School states that qualified full-time research postgraduate students may receive postgraduate studentships, with the 2026/27 annual studentship set at HK$229,200 during the normative period (CUHK studentships). CUHK lists research postgraduate tuition at HK$47,000 per year for 2026/27 and HK$49,500 for 2027/28, plus a HK$500 application fee (CUHK fees). RGC's Hong Kong PhD Fellowship Scheme is more generous: for 2026/27 it provides HK$344,400 annual stipend and HK$14,400 annual conference/research-related travel allowance for up to three years (RGC HKPFS). CUHK's own HKPFS page describes additional university-level package elements for awardees (CUHK HKPFS).

The project description itself does not confirm which of these applies. It should not be treated as fully funded until the supervisor or graduate division confirms stipend or salary, tuition responsibility, and whether the candidate is admitted as a research postgraduate, employed as a research assistant, or first hired as an RA with later PhD application.

Living-cost interpretation depends heavily on housing. CUHK Postgraduate Halls list 2026/27 monthly fees of roughly HK$2,065-2,740 for shared rooms and HK$3,480-4,135 for single rooms, excluding air-conditioning, laundry and meals (Postgraduate Hall fees). CU Medicine notes that postgraduate students can choose on- and off-campus options, and that hostel fees include electricity, water and internet but not air-conditioning, laundry or meals (CU Medicine accommodation). Hong Kong's broader private-rental cost base is materially higher; official cost-of-living data for households renting privately show housing, food and transport can dominate monthly budgets (Hong Kong cost of living).

A practical applicant should model three cases:

• Regular CUHK studentship plus on-campus hostel: likely workable if tuition is covered/waived as applicable.
• Regular studentship plus private rental: financially tighter.
• HKPFS or enhanced package: substantially more comfortable and better for conference/research travel.

Applicant Fit and Preparation

Best suited for

• Biomedical, neuroscience, molecular biology, bioengineering, genetics, computational biology or medical-science candidates.
• Applicants with hands-on evidence in at least one core platform: CRISPR, AAV, animal models, primary cell/tissue culture, organotypic slices, high-throughput screening, sequencing, or computational biology.
• Candidates comfortable working between wet-lab biology and quantitative data analysis.
• Applicants who want basic and translational disease-mechanism work rather than a purely clinical neurology route.

May need caution if

• The applicant wants mainly patient-facing clinical work with little experimental biology.
• The applicant is unwilling to work with animal models, tissue culture, viral vectors or long optimization cycles.
• The applicant has only coursework interest in neuroscience and no research evidence.
• The applicant needs funding certainty before applying and cannot proceed without a written package confirmation.

Skills and evidence to strengthen

Strong evidence would include a concise research-fit statement, a methods table separating hands-on and assisted experience, a thesis abstract or writing sample, and any reproducible analysis portfolio. For wet-lab candidates, the biggest add-on is sequencing/statistical literacy. For computational candidates, the biggest add-on is enough experimental understanding to design analyses around real biological constraints. The official CUHK programme page says applicants should preferably hold a bachelor's degree with honours in a biomedical or life-science-related field and shortlisted applicants may be interviewed (programme page). RGC's HKPFS criteria also emphasize academic excellence, research potential, communication/interpersonal skills and leadership (RGC HKPFS).

Advertised eligibility and application materials

The job notice asks for a bachelor's degree or higher in a relevant discipline, good communication and teamwork, proficiency in written and spoken English, and a strong command of one or more listed areas: CRISPR, AAV engineering/production, animal models, primary-cell/tissue culture, high-throughput in vivo/in vitro genetic or pharmacological screening, bulk/single-cell DNA/RNA sequencing, or computational biology. Applicants should email a cover letter, CV, academic transcripts and proof of English-language ability if available to yingjunliu@cuhk.edu.hk. The saved page's “STATUS: EXPIRED” label conflicts with its future-dated deadline, so present availability remains unconfirmed.

Risks and Questions to Verify

High-priority questions

1. Are both advertised openings funded PhD places, research-assistant jobs, or flexible RA-to-PhD routes?
2. What exact stipend or salary applies, and is tuition fully covered, waived, or paid by the student?
3. Which CUHK intake year and application route should be used for the stated 30 November 2026 project deadline?
4. Is HKPFS expected, optional, or separate from this opportunity?
5. What is the start date, contract duration, and expected weekly balance between coursework, lab work, RA duties and thesis research?
6. Which first-year platform will be prioritized: CRISPR/AAV, organotypic slice culture, animal models, high-throughput screening, sequencing, computational biology, or a mix?

Medium-priority questions

1. How many PhD students, postdocs and research assistants are currently in the CUHK lab?
2. Which core facilities and approvals are already in place for AAV, animal work, slice culture and sequencing?
3. Will the candidate be formally based in the School of Biomedical Sciences, Gerald Choa Neuroscience Institute, or both?
4. What collaboration links remain active with Zurich, ETH, Shenzhen, or other partners?
5. What publication and conference expectations apply in the first two years?
6. Is on-campus postgraduate housing likely or supported for this role?

Evidence and Sources

• Prof. Yingjun Liu profile and research interests: GCNI, CUHK research portal, ETH Zurich profile
• CUHK and programme environment: Graduate School overview, MPhil-PhD Biomedical Sciences, CU Medicine postgraduate study, CUHK School of Biomedical Sciences
• Rankings: CUHK rankings, THE profile, ShanghaiRanking
• Funding and costs: CUHK studentships, CUHK fees, RGC HKPFS, CUHK HKPFS, Postgraduate Hall fees, CU Medicine accommodation, Hong Kong cost of living
• Recent supervisor/lab publications: Nature Neuroscience 2024, Communications Biology 2022 DOI, EMBO Journal 2022, Cell 2026, Glia 2020 DOI
• Field and career context: WHO dementia fact sheet, Nature Reviews Neuroscience 2024, Nature 2024 CRISPR aging screen, Hong Kong Talent Engage I&T professions, Hong Kong I&T strategy release